LCM
ACOR

Laurion Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Laurion Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-93
Closed -$219K – 1961
2017
Q2 		$219K Buy
+93
New +$184K ﹤0.01% 1524
2016
Q2 		– Sell
-89
Closed -$283K – 1080
2016
Q1 		$283K Buy
+89
New +$369K ﹤0.01% 613

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Laurion Capital Management's ACOR Position: Q3 2017 in Review

Laurion Capital Management sold out of Acorda Therapeutics (ACOR) in Q3 2017, closing a stake of 93 shares — an estimated $219K sold.

Laurion Capital Management first reported a position in ACOR in Q1 2016 and held it in 2 quarters. The position peaked at $283K in Q1 2016. 152 funds tracked by Wall St. Rank hold ACOR as of Q3 2017.

  • Laurion Capital Management reported no remaining Acorda Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Laurion Capital Management sold 93 Acorda Therapeutics shares in Q3 2017, an estimated $219K.
  • Laurion Capital Management first reported a position in Acorda Therapeutics in Q1 2016 and held it in 2 quarters.
  • Laurion Capital Management's Acorda Therapeutics position peaked at $283K in Q1 2016.
  • 152 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2017.

Based on Laurion Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.